After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...
Jan 3 (Reuters) - Shares of drug developer Dyne Therapeutics (DYN.O), opens new tab jumped 18% on Wednesday after its experimental therapy for a muscle-wasting disorder called Duchenne muscular ...
Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders. It has seven programs in its pipeline, but only two are in clinical trials. Dyne focuses on treating ...
Hosted on MSN
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy ...
Hosted on MSN
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne Therapeutics announced that its investigational therapy, called DYNE-251, ...
Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...
Shares of Dyne Therapeutics (NASDAQ:DYN) dropped ~21% in the premarket on Tuesday after the company indicated a delay in filing for U.S. approval of DYNE-101, an experimental therapy for a rare muscle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback